DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M. Henricks, Jan H.M. Schellens, Geert-Jan Creemers et al.|The Lancet Oncology|2018Cited by 419
HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53Didier Meulendijks, Annemieke Cats|British Journal of Cancer|2015Cited by 113
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapyMarkus Joerger, Jan H.M. Schellens, Alwin D. R. Huitema et al.|Cancer Chemotherapy and Pharmacology|2015Cited by 55